Is ESTA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on United States share gain against a two-brand incumbency, with revenue (ttm) at ~$246 million, up ~39% year over year. The bear case rests on the balance sheet is the first thing to weigh: roughly $264 million of debt against about $71 million of cash, secured by a first-priority lien on substantially all assets, at a company that has not yet generated positive free cash flow. Analysts covering it are spread from $84.00 to $117.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The balance sheet is the first thing to weigh: roughly $264 million of debt against about $71 million of cash, secured by a first-priority lien on substantially all assets, at a company that has not yet generated positive free cash flow. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $84.00, +6.3% from the $79.05 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

United States share gain against a two-brand incumbency. The US aesthetic breast market has been effectively a duopoly between Allergan's Natrelle and Mentor for over a decade, and Motiva is the first new entrant to clear the FDA since 2013. The most optimistic analyst target on ESTA is $117.00, +48.0% from the $79.05 price. That figure is only reachable if this thesis works close to its best case.

The balance sheet is the first thing to weigh: roughly $264 million of debt against about $71 million of cash, secured by a first-priority lien on substantially all assets, at a company that has not yet generated positive free cash flow. Interest expense of about $7.0 million a quarter is now larger than adjusted EBITDA, so the path to GAAP profit depends on continued volume growth rather than on cost cuts. Demand is discretionary and cash-pay: breast augmentation is elective and consumer-financed, which historically makes procedure volumes sensitive to consumer confidence and credit conditions, and the company has already seen weakness in individual markets including China. Competitive response is unpriced, since AbbVie and Johnson & Johnson are vastly larger and can meet a share threat with price or bundling. The company also carries a credibility overhang from an October 2022 Hindenburg Research report questioning conflicts of interest in its safety studies, which triggered multiple law-firm investigations at the time, and separate accounting-focused allegations in 2019. Finally, the stock is thinly capitalized relative to its multiple, with about 29 million shares outstanding, and it has moved more than 10% in a single session on earnings. The most pessimistic published target is $84.00, +6.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Establishment Labs makes Motiva breast implants and minimally invasive breast procedures, and is taking US share after its FDA approval in September 2024.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (United States share gain against a two-brand incumbency) stalling in the reported numbers rather than in the narrative, the risk above (the balance sheet is the first thing to weigh: roughly $264 million of debt against about $71 million of cash, secured by a first-priority lien on substantially all assets, at a company that has not yet generated positive free cash flow) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Silicone breast implants and related devices under the Motiva brand, manufactured at two company-owned plants in Costa Rica and sold in roughly 85 countries. The lineup includes SmoothSilk Ergonomix and Round implants, the Motiva Flora tissue expander for post-mastectomy reconstruction, and two minimally invasive procedure platforms, Mia Femtech and Preservé. Revenue was about $246 million over the trailing twelve months to June 2026.

Revenue of $67.5 million beat the roughly $65.8 million consensus and management raised full-year guidance to $269 million to $271 million, but the per-share loss of $0.39 came in wider than the $0.34 analysts expected. Shares fell about 13% on August 6, 2026, to roughly $79. The pattern reflects a market that is willing to pay a high sales multiple but reacts sharply when the profitability timeline slips.

Not on a GAAP basis. The company lost about $11.7 million in the second quarter of 2026 and roughly $38.9 million over the trailing twelve months. Adjusted EBITDA, which excludes stock compensation and other items, turned positive at about $3.7 million and has now been positive for three consecutive quarters. Free cash flow was still negative in the first half, with about $20.9 million of operating cash used, though that improved from $39.5 million a year earlier.